ELISA POSE (@poseelisa) 's Twitter Profile
ELISA POSE

@poseelisa

Hepatologist with a special interest in alcohol related liver disease.

ID: 1509268098553102337

calendar_today30-03-2022 20:36:21

78 Tweet

262 Followers

171 Following

Albrecht Neesse (@albrechtneesse) 's Twitter Profile Photo

UEGJ constant flow of papers 🔥 Editors exchange & discuss daily 👍👎 Quick and fair decisions 💪Send us your best work - we make it even better 👌Promotion via visual abstracts & social media Keith Siau Daniel Keszthelyi MD PhD RFF Yasuko Maeda Konrad Aden Andrea Anderloni ELISA POSE

Ramon Bataller (@rabataller) 's Twitter Profile Photo

MetALD: metabolic syndrome & moderate alcohol 🔸How can we diagnose it ? 🔸Does it impact patient's outcomes? 🔸Why are they synergistic ? In this review, we explain it all. t.ly/uXn7f ELISA POSE Jordi Gratacós Ginès

MetALD: metabolic syndrome & moderate alcohol

🔸How can we diagnose it ?
🔸Does it impact patient's outcomes? 
🔸Why are they synergistic ?

In this review, we explain it all.

t.ly/uXn7f <a href="/PoseElisa/">ELISA POSE</a> <a href="/JordiGratacos8/">Jordi Gratacós Ginès</a>
Elliot Tapper (@ebtapper) 's Twitter Profile Photo

BREAKING: rifaximin and simvastatin did not help people with decompensated cirrhosis Congratulations to ELISA POSE And congrats to JAMA for getting this paper

BREAKING: rifaximin and simvastatin did not help people with decompensated cirrhosis 

Congratulations to <a href="/PoseElisa/">ELISA POSE</a> 
And congrats to <a href="/JAMA_current/">JAMA</a> for getting this paper
IDIBAPS (@idibaps) 's Twitter Profile Photo

🆕Investigadors del #CLÍNIC-#IDIBAPS i del CIBERehd han liderat un estudi europeu per avaluar l'eficàcia d'una combinació de tractaments en pacients amb #cirrosi descompensada 👉s.mtrbio.com/bgzaejyqqe #LiverScreen #LiverAim #liverdisease

🆕Investigadors del #CLÍNIC-#IDIBAPS i del <a href="/CIBERehd/">CIBERehd</a> han liderat un estudi europeu per avaluar l'eficàcia d'una combinació de tractaments en pacients amb #cirrosi descompensada

👉s.mtrbio.com/bgzaejyqqe

#LiverScreen #LiverAim #liverdisease
Jasmohan Bajaj (@jasmohanbajaj) 's Twitter Profile Photo

When negative is also positive! Eagerly awaited effort by ELISA POSE & the talented LIVERHOPE consortium!! Lots of important teaching points will emerge. Till then decompensated #cirrhosis remains a challenge The Baveno Cooperation: an EASL Consortium EASLnews AASLD ACG

LiverAim (@liveraim) 's Twitter Profile Photo

#Chronicliverdisease is a public health thread. #earlydiagnosis can improve patients' outcomes & QoL. ❓What does an early diagnosis mean for patients, families & caregivers? 🗓️3 March 17:30-18:10 CET 👉 Join the second #LIVERAIM webinar! liveraim.eu/2025/02/10/ear…

#Chronicliverdisease is a public health thread. #earlydiagnosis  can improve patients' outcomes &amp; QoL.  

❓What does an early diagnosis mean for patients, families &amp; caregivers?   

🗓️3 March 17:30-18:10 CET  

👉 Join the second #LIVERAIM webinar! liveraim.eu/2025/02/10/ear…
Gastroenterology (@aga_gastro) 's Twitter Profile Photo

⏪ Let's take a look back at one of Gastro's most engaging articles from this time last year, a commentary on the renaming of #NAFLD. Read the article here: ow.ly/IMPb50V0ruU

⏪ Let's take a look back at one of Gastro's most engaging articles from this time last year, a commentary on the renaming of #NAFLD. Read the article here: ow.ly/IMPb50V0ruU
Asociación Española para el Estudio del Hígado (@aeehliver) 's Twitter Profile Photo

🔛Interesante investigación presentada por Jordi Gratacós Ginès sobre diagnóstico de la Enfermedad hepática por alcohol (ALD) en población general. ✔️4.198 participantes incluidos en el estudio, 1.930 (46%) tuvieron SLD: 64 (3%) ALD, 216 (11%) MetALD, 1.639 (85%) MASLD y 11 (1%) ✔️Los

🔛Interesante investigación presentada por <a href="/JordiGratacos8/">Jordi Gratacós Ginès</a> sobre diagnóstico de la Enfermedad hepática por alcohol (ALD) en población general.
✔️4.198 participantes incluidos en el estudio, 1.930 (46%) tuvieron SLD: 64 (3%) ALD, 216 (11%) MetALD, 1.639 (85%) MASLD y 11 (1%)
✔️Los
Queralt Herms (@queraltherms) 's Twitter Profile Photo

T’interessa l’especialitat d’Aparell Digestiu? Descobreix el nou itinerari formatiu dels 4 anys de residència a l’Hospital Clínic! No dubtis a preguntar-nos qualsevol dubte. Vine a conèixer-nos el 20 de març, t’hi esperem! 😉 LiverUnit.Clinic.BCN Liver ICU Servei Gastroenterologia Hospital Clínic Barcelona

T’interessa l’especialitat d’Aparell Digestiu? Descobreix el nou itinerari formatiu dels 4 anys de residència a l’<a href="/hospitalclinic/">Hospital Clínic</a>!

No dubtis a preguntar-nos qualsevol dubte. Vine a conèixer-nos el 20 de març, t’hi esperem! 😉

<a href="/liverunitclinic/">LiverUnit.Clinic.BCN</a> <a href="/LiverIcu/">Liver ICU</a> <a href="/gasclinicbcn/">Servei Gastroenterologia Hospital Clínic Barcelona</a>
IDIBAPS (@idibaps) 's Twitter Profile Photo

4x LIVER SEMINAR🧵 1️⃣Cellular interactions in liver injuries and regeneration - focus on the portal area 📆10/06, 15.15h 👨‍🔬Adrien Guillot, Charité university of medicine (Berlin)  📍 Esteve Auditorium, CEK 👉f.mtr.cool/kdzsomwwau

4x LIVER SEMINAR🧵

1️⃣Cellular interactions in liver injuries and regeneration - focus on the portal area

📆10/06, 15.15h
👨‍🔬Adrien Guillot, Charité university of medicine (Berlin) 
📍 Esteve Auditorium, CEK

👉f.mtr.cool/kdzsomwwau
IDIBAPS (@idibaps) 's Twitter Profile Photo

3️⃣Mechanisms and clinical implications of inflammation in steatohepatitis 📆11/06, 15.15h 👨‍🔬Gyongyi Szabo, Harvard Medical School, Boston 📍 Esteve Auditorium, CEK 👉f.mtr.cool/xubktyuuut

3️⃣Mechanisms and clinical implications of inflammation in steatohepatitis

📆11/06, 15.15h
👨‍🔬Gyongyi Szabo, Harvard Medical School, Boston
📍 Esteve Auditorium, CEK

👉f.mtr.cool/xubktyuuut